NCT05207709: An ongoing trial by SOLTI Breast Cancer Research Group
This trial is ongoing. It must report results 1 year, 2 months from now.
Full data
| Full entry on ClinicalTrials.gov | NCT05207709 |
|---|---|
| Title | A Phase III, Multicenter, Open-label Study of Ribociclib vs. Palbociclib in Patients With Advanced Hormone Receptor-positive/HER2-negative/HER2-Enriched Breast Cancer - HARMONIA Trial |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | March 28, 2022 |
| Completion date | March 1, 2026 |
| Required reporting date | March 1, 2027, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |